# A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

Source: https://onco.cc/trials/nct05731271/  
OnCo record `nct05731271` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TST003 in colorectal cancer, run by Transcenta Therapeutics (Hangzhou) Co., Ltd., active and no longer recruiting.

## Summary

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT05731271 by Transcenta Therapeutics (Hangzhou) Co., Ltd., with 111 participants enrolled, started 2023-02-08 and due to reach its primary completion in 2026-06. Interventions recorded: TST003.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05731271
- Phase: 1/2
- Setting: A First-in-Human, Open-Label, Multi-Center Phase 1 Study of TST003 in Subjects With Locally Advanced or Metastatic Solid Tumors
- Sponsor: Transcenta Therapeutics (Hangzhou) Co., Ltd.
- Enrolled: 111

## Sources

- ClinicalTrials.gov NCT05731271: https://clinicaltrials.gov/study/NCT05731271

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [TST003](https://onco.cc/drugs/tst003/)

---
JSON: https://onco.cc/api/v1/entities/nct05731271.json